Idorsia Pharmaceuticals Ltd

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023

In its 2023 reporting, Idorsia Pharmaceuticals Ltd disclosed greenhouse gas emissions of 982.8 tCO2e (Scope 1 & 2). By scope: Scope 1: 475.0 tCO2e; Scope 2: 507.8 tCO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
982.8 tCO2e (Scope 1 & 2)
2023
⚡
Renewable Energy
100% (headquarters electricity)
of total energy
💧
Water Usage
33.68 ML
2023
♻️
Waste
305.1 tons
2023
⚙️
Energy Use
15.8K MWh
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).475.0 tCO2e
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.507.8 tCO2e

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

📅 Medium-term

  • Increase energy efficiency by 4.7% and decrease CO2 emissions by 20% at headquarters from 2016 to 2025 (agreement with Federal Offices for the Environment and Energy)

🌱 ESG Focus Areas

Advancing science and healthcareSafeguarding and developing talent and fostering diversityCompliance and business ethicsEnvironmental impact management

⚠️ Challenges & Risks +

  • Financial challenges impacting ability to invest in new sustainability initiatives, collect data, and monitor impact
  • Staff reductions due to financial constraints
  • Lower-than-anticipated product sales and a difficult global financial environment

📋 Report Information

Reporting Period: 2023
Frameworks: GRI 2021 Standards, TCFD (initial assessment completed)